CNBX Pharmaceuticals Inc.
CNBX evidence brief
What we can confirm
- Market Cap:
- $321K
What it means
What to watch
Prepared research question
What matters most for CNBX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CNBX
CNBX Pharmaceuticals Inc. (CNBX) is a biotech company with no reported revenue or cash as of May 2026, and no disclosed clinical-stage assets or pipeline programs in the provided data.
Key risk: No cash runway
Market Cap
$321K
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of May 31, 2026.
CNBX Pharmaceuticals Inc. (CNBX) is a biotech company with no reported revenue or cash as of May 2026, and no disclosed clinical-stage assets or pipeline programs in the provided data.
- As of 2026-05-31, CNBX reported $0.0M in cash & equivalents and $0.0M in total revenue [sec].
- Net income was -$0.2M and shareholders' equity was -$2.7M as of 2026-05-31 [sec].
- No clinical trials, regulatory filings, or product candidates for CNBX are described in the available data [competitor_trial].
What to weigh
- CNBX has no reported revenue and negative shareholders' equity of -$2.7M as of 2026-05-31, indicating a structurally challenged financial position [sec].
- The company has no disclosed clinical-stage assets or pipeline programs in the provided data, suggesting a lack of near-term product development activity [competitor_trial].
Risks & what to watch (3)›
Key risks
- No cash runway — Cash & equivalents were $0.0M as of 2026-05-31, indicating no immediate liquidity [sec].
- Negative equity — Shareholders' equity was -$2.7M as of 2026-05-31, reflecting liabilities exceeding assets [sec].
- No disclosed pipeline — No clinical trials or product candidates for CNBX are mentioned in the provided data [competitor_trial].
What to watch
- Any future SEC filings or press releases that might disclose new financing, partnerships, or pipeline developments [sec].
Sources: Competitor trials · Generated October 5, 2026 · How we verify sources →
Run CNBX Pharmaceuticals Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CNBX Pharmaceuticals Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Dec 2024Institutional holders
1
Total value held
$0
| Holder | Shares | Value |
|---|---|---|
| archer investment corp | 9 | $0 |
Governance
Frequently asked questions
What is the AI investment thesis for CNBX Pharmaceuticals Inc.?
CNBX Pharmaceuticals Inc. (CNBX) is a biotech company with no reported revenue or cash as of May 2026, and no disclosed clinical-stage assets or pipeline programs in the provided data.
Who is the CEO of CNBX Pharmaceuticals Inc.?
Mr. Eyal Barad is the chief executive officer of CNBX Pharmaceuticals Inc. (CNBX).
Where is CNBX Pharmaceuticals Inc. headquartered?
CNBX Pharmaceuticals Inc. (CNBX) is headquartered in Bethesda, MD, United States.
What therapeutic areas does CNBX Pharmaceuticals Inc. focus on?
CNBX Pharmaceuticals Inc. develops therapies across Oncology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.